Skip to main content

Table 4 Serious adverse events for the groups either receiving or not receiving plasma exchange (PEX) as part of disease induction. Data are given as number of patients (%)

From: Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service

Severe adverse events Number (%) No PEX (n = 46) PEX (n = 58) p value
All severe adverse events    
Number of adverse events 21 15 0.04
Number (%) of patients 15 (33) 12 (21) 0.26
Serious infections, number of events 10 7 0.29
Chest 6 5 0.53
Urine 2 2 1
Pneumocystis jirovecii pneumonia 2 0 0.19
Other hospitalizations, number of events 4 5 1
Fractures 2 2 1
Cardiovascular 2 3 1
Malignancy 2 0 0.19
Death 5 3 0.46